Formulary Group work programme


Forthcoming submissions 2014

This list is indicative and may be subject to change.

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Certolizumab pegol- SMC 973/14-Formulary Group advice will be published by 30th September 2014. (Indication: in combination with methotrexate, for the treatment of active psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug (DMARD) therapy has been inadequate).

Eltrombopag - SMC 919/13 - in progress. (Indication: in adult patients with chronic hepatitis C virus infection, for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy).

Nalmefene - SMC 917/13 - in progress. (Indication: for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification).

Nepafenac - SMC 813/12 - in progress. (Indication: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: Prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations:Management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Ocriplasmin - SMC 892/13 - in progress.(Indication: in adults for the treatment of vitreomacular traction).

Rituximab subcutaneous injection- SMC 975/14- in progress.(Indication: for non-Hodgkin's lymphoma (NHL) in adults).

Tocilizumab - SMC 982/14 -Formulary Group advice will be published by 30th September 2014. (Indication: in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients).

Ustekinumab - SMC 944/14 -Formulary Group advice will be published by 30th September 2014. (Indication: alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

Previous: Formulary Group | Top | Next: Formulary Group decisions index